Inicio > Cardiología > Comportamiento de la Cardiopatía Isquémica en pacientes Hipertensos > Página 16

Comportamiento de la Cardiopatía Isquémica en pacientes Hipertensos

6. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33: 1635-701.

7. Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective Studies. J Hypertens. 2012; 30:449-56.

8. Stamler J, Vaccaro O, Neaton DJ, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993; 16(2):434-44.

9. Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9.

10. González J L, Capote M L. Modificación de factores de riesgo en pacientes sometidos a educación en RC. Instituto Cardiovascular del Hospital Clínico San Carlos de Madrid, España. 2009.

11. Comportamiento de los factores de riesgo coronario en pacientes rehabilitados en el Hospital Hermanos Ameijeiras. Rev Cubana Cardiol Cir Cardiovasc 2012; 18(4):199-203.

12. The ONTARGET Investigastors. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med. 2008; 358:1547-59.

13. Patel A; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patietns with type 2 diabetes: a ranodmised controlled trial. Lancet. 2009; 370:829- 40.

14. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. N Engl J Med. 2008; 359:2417-28.

15. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, et al. ESH position paper: renal denervation — an interventional therapy of resistant hypertension. J Hypertens. 2012; 1 30:837-41.

16. Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, et al. Costeffectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012; 60:1271-7.

17-Alfonso F, Bermejo J, Segovia J. Enfermedades cardiovasculares en la mujer: ?por qué´ ahora? Rev Esp Cardiol. 2006; 59:259–63.

18- Alfonso F, Segovia J, Heras M, Bermejo J. Patologı´a arterial no coronaria: ?de interés para el cardio´ logo? Rev Esp Cardiol. 2007; 60:179–83.

19. Alfonso F, Segovia J, Heras M, Bermejo J. Prevencio´n cardiovascular: ?siempre demasiado tarde? Rev Esp Cardiol. 2008; 61:291–8.

20. Bermejo J, Heras M, Segovia J, Alfonso F. Medicina cardiovascula r traslacional. Ahora o nunca Rev Esp Cardiol. 2009; 62:66–8.

21. Segovia J, Bermejo J, Alfonso F, Heras M. Corazo´n derecho y circulacio´n pulmonar: ?una circulacio´n menor? Rev Esp Cardiol. 2010; 63:77–80.

22. Pérez de Isla L, Avanzas P, Bayes-Genis A, Sanchis J, Heras M. Enfermedades siste´micas y corazo´ n: introduccio´ n. Rev Esp Cardiol. 2011; 64:60–1.

23. Bayes-Genis A, Avanzas P, Pe´ rez de Isla L, Sanchis J, Heras M. Arritmias: introduccio´ n. Rev Esp Cardiol. 2012; 65:91.

24. Avanzas P, Bayes-Genis A, Pe´ rez de Isla L, Sanchis J, Heras M. Innovacio´n en cardiologı´a: introduccio´ n. Rev Esp Cardiol. 2013; 66:133.

25. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Documento de consenso de expertos. Tercera definicio´n universal del infarto de miocardio. Rev Esp Cardiol. 2013; 66:132.e1–15.

26. Steg G, James SK, Atar D, Badano LP, Blomstrom Lundqvist C, Borger MA, et al. Guía de pra ctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevacio´n del segmento ST. Rev Esp Cardiol. 2013; 66:53.e1–46.

27. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Rev ESP Cardiol.2012; 65:173.e1–55.

28. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey Jr DE, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61:e179–347.

29. O’Gara PT, Kushner FG, Ascheim DD, Casey Jr DE, Chung MK, De Lemos JA, et al; American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions. 2013 ACCF/AHA guideline for the management of STelevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61:e78–140. Rev Esp Cardiol. 2014; 67(2):138.

30. De´gano IR, Elosua R, Marrugat J. Epidemiologia del síndrome coronario agudo en España: estimación del número de casos y la tendencia de 2005 a 2049. Rev ESP Cardiol. 2013; 66:472–81.

31. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013; 127:143–52.

32. Huffman MD, Lloyd-Jones DM, Ning H, Labarthe DR, Guzman Castillo M, O’Flaherty M, et al. Quantifying options for reducing coronary heart disease mortality by 2020. Circulation. 2013; 127:2477–84.

33. Sánchez-Cruz JJ, Jime’nez-Moleo’n JJ, Fernández-Quesada F, Sánchez MJ. Prevalencia de obesidad infantil y juvenil en España en 2012. Rev Esp Cardiol. 2013; 66:371–6.

34. Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, et al. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol. 2013; 61:1607–15.

35. Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. J Am Coll Cardiol. 2013; 61:1–11.

36. Estruch R, Ros E, Salas-Salvado´ J, Covas MI, Corella D, Arós F, et al; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013; 368:1279–90.

37. Parving HH, Brenner BM, McMurray JJV, De Zeeuw D, Haffer SM, Solomon SD, et al; ALTITUDE Investigators. Cardio renal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012; 367:2204-13. Pérez LM., et al.

38. Dehghan M, Mente A, Teo KK, Gao P, Sleight P, Dagenais G, et al. Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention. Circulation. 2012; 126:2705–12.